Cortical Excitability in West Syndrome Using Transcranial Magnetic Stimulation

Launched by ALL INDIA INSTITUTE OF MEDICAL SCIENCES · Jan 1, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how the brain's excitability, or responsiveness, changes in children with West Syndrome before and after treatment with ACTH therapy, a common medication for this condition. West Syndrome is a type of epilepsy that begins in infancy and is often associated with developmental delays. The researchers hope to understand if changes in brain excitability can help predict how well a child will respond to ACTH therapy, particularly in reducing the frequency of seizures over a 12-week period.

To be eligible for this study, children between 6 months and 2 years old who have been diagnosed with West Syndrome and have had a recent sleep EEG (a test that monitors brain activity) are being recruited. The study is looking for families who are willing to consider ACTH therapy or a ketogenic diet as treatment options. Participants will undergo assessments to measure brain excitability and will be monitored throughout the study to see how their condition evolves with treatment. This research aims to provide new insights into childhood epilepsy, which may help improve future treatments and outcomes for affected children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Children, aged 6 months - 2 years with electroclinical diagnosis of West syndrome
• • Sleep EEG available within last 1 week before screening.
• • Screen for tuberculosis (Chest X-ray PA view and Mantoux testing) negative
• • Parents willing for ACTH or Ketogenic Diet therapy
• Exclusion Criteria:
• • Already on ACTH, prednisolone vigabatrin or KD therapy \> 5days
• • Tuberous sclerosis
• • Vitamin trial responsiveness
• • Known Pre-existing contraindications for KD (IEM, Porphyria etc.)
• • Chronic systemic illness (Ex: Chronic kidney disease, congenital heart diseases etc)
• • Parents refusing consent for enrolment in the study.